CN115089755A - Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof - Google Patents
Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof Download PDFInfo
- Publication number
- CN115089755A CN115089755A CN202210896194.2A CN202210896194A CN115089755A CN 115089755 A CN115089755 A CN 115089755A CN 202210896194 A CN202210896194 A CN 202210896194A CN 115089755 A CN115089755 A CN 115089755A
- Authority
- CN
- China
- Prior art keywords
- skin
- alginate
- medical dressing
- dressing composition
- repairing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 37
- 108010035532 Collagen Proteins 0.000 title claims abstract description 37
- 229920001436 collagen Polymers 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000000694 effects Effects 0.000 title abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 238000003756 stirring Methods 0.000 claims abstract description 19
- 235000011187 glycerol Nutrition 0.000 claims abstract description 17
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940072056 alginate Drugs 0.000 claims abstract description 16
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 16
- 229920000615 alginic acid Polymers 0.000 claims abstract description 16
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 11
- 239000000661 sodium alginate Substances 0.000 claims abstract description 11
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000000835 fiber Substances 0.000 claims description 10
- 230000035876 healing Effects 0.000 claims description 8
- 229920000742 Cotton Polymers 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000004744 fabric Substances 0.000 claims description 4
- -1 pentapeptide-3 Chemical compound 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 3
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 claims description 2
- OFGVZFQUFJYSGS-CPDXTSBQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OFGVZFQUFJYSGS-CPDXTSBQSA-N 0.000 claims description 2
- QNZANUZIBYJBIN-XSWJXKHESA-N (3s)-3-[[(2s)-2-acetamido-5-amino-5-oxopentanoyl]amino]-4-[[(2s)-1-[[(1s)-1-carboxy-2-(1h-imidazol-5-yl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound NC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QNZANUZIBYJBIN-XSWJXKHESA-N 0.000 claims description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 2
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 2
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 2
- 229920006052 Chinlon® Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 2
- 244000082204 Phyllostachys viridis Species 0.000 claims description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 229920001131 Pulp (paper) Polymers 0.000 claims description 2
- 229920000297 Rayon Polymers 0.000 claims description 2
- 229920002334 Spandex Polymers 0.000 claims description 2
- 229920004933 Terylene® Polymers 0.000 claims description 2
- 229920006221 acetate fiber Polymers 0.000 claims description 2
- 229940086540 acetyl tetrapeptide-9 Drugs 0.000 claims description 2
- 235000010407 ammonium alginate Nutrition 0.000 claims description 2
- 239000000728 ammonium alginate Substances 0.000 claims description 2
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 claims description 2
- 229920006231 aramid fiber Polymers 0.000 claims description 2
- 239000011425 bamboo Substances 0.000 claims description 2
- 235000009120 camo Nutrition 0.000 claims description 2
- 235000005607 chanvre indien Nutrition 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 239000011487 hemp Substances 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004745 nonwoven fabric Substances 0.000 claims description 2
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920006306 polyurethane fiber Polymers 0.000 claims description 2
- 235000010408 potassium alginate Nutrition 0.000 claims description 2
- 239000000737 potassium alginate Substances 0.000 claims description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- 239000004759 spandex Substances 0.000 claims description 2
- 210000002268 wool Anatomy 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 13
- 206010052428 Wound Diseases 0.000 abstract description 10
- 239000008213 purified water Substances 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 239000012567 medical material Substances 0.000 abstract description 2
- 230000003020 moisturizing effect Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract 2
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 230000000474 nursing effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 24
- 102000016359 Fibronectins Human genes 0.000 description 11
- 108010067306 Fibronectins Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 206010072170 Skin wound Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000001223 reverse osmosis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000037314 wound repair Effects 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000010005 growth-factor like effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 208000023929 Degloving injury Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000009518 penetrating injury Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0033—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0042—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of medical materials, in particular to a medical dressing composition of recombinant fibronectin-humanized collagen and a preparation method thereof. The composition consists of a base material and a liquid medicament attached to the base material, wherein the preparation raw materials of the liquid medicament contain recombinant fibronectin-humanized collagen, active peptide, sodium alginate and glycerol. The preparation method of the dressing composition comprises mixing recombinant fibronectin-humanized collagen, active peptide and purified water, dissolving, adding alginate and glycerol, and stirring at high speed to obtain gel dressing. The medical dressing with the effects of moisturizing, wound repairing, dermatitis treatment, superficial injury treatment and wound surface nursing is obtained by matching and using the recombinant fibronectin-humanized collagen, the active peptide, the alginate and the glycerol, and coordinating and synergizing.
Description
Technical Field
The invention belongs to the technical field of medical materials, and particularly relates to a medical dressing with a repairing effect.
Background
Fibronectin (FN) is a multifunctional protein existing in human tissues and cells, is a high-molecular and high-activity glycoprotein, is a protein dimer, is composed of two similar subunits, is formed by crosslinking through a C-terminal disulfide bond, and has a V-shaped whole molecule and a molecular weight of 440-450 KDa. The molecular weight of each subunit is 220-250 kDa. Fibronectin in human blood, cell surface, clinically demonstrated: fibronectin stimulates skin cells to produce collagen, thereby restoring skin elasticity. Comprehensively regenerating cells of each layer of skin: not only can resist aging, but also can comprehensively repair red blood streak and allergic skin. Comprehensively repairing cells of each layer of skin: phagocytizing and cleaning pathogenic bacteria and harmful components in cell living environment, and allowing skin to generate various moisturizing nutritional factors (hyaluronic acid and ceramide), thereby regulating moisture from inside to outside to moisten skin.
Collagen is a biological high molecular substance, and is a white, opaque, unbranched fibrous protein. Collagen is the main component in human skin, accounts for 70% -80% of extracellular matrix, and forms a fine elastic net in skin to lock water, and the skin is supported like a bracket, so that the skin is full of elasticity, moist, fine and smooth. The collagen industry has been in history for decades abroad, and based on developed economic foundations, advanced biotechnology, mature industry environment and green and healthy consumption concept, the collagen market in Europe and America is relatively mature, and collagen foods, health care products and cosmetics become products favored by people in Europe and America, Japan and other developed countries and are widely applied.
Fibronectin has wide application and huge market in the fields of medicine, cosmetics and scientific research, but the yield of natural and high-purity fibronectin extracted from human or animal blood and tissues is extremely limited and the cost is high. Limiting the use and production of FN in many ways. The traditional collagen is mainly extracted from animal connective tissues, but has risks of animal-derived diseases and the like, and the prepared collagen product has weaker tensile strength, faster degradation of pure collagen in vivo and possible potential antigenicity and the like, and simultaneously, due to the difference of the collagen source, the processing technology and the raw material proportion, the nutritional ingredients and the use values of the product are different, and the leather is not only contacted with a plurality of chemical substances in the processing process, but also is easily infected by bacteria, thereby greatly limiting the potential application and development of the leather.
The recombinant fibronectin-humanized collagen is an integrated protein which is developed by Wuxi Meishangjie biotechnology limited and has the effects of fibronectin and type III collagen at the same time. Fibronectin is widely involved in the processes of cell migration, adhesion, proliferation, hemostasis, tissue repair and the like, mobilizes a mononuclear phagocyte system to remove harmful substances at the damaged tissue, and has a growth factor-like effect. Humanized collagen is mainly found in skin, vascular intima and intestinal tract of infants. The collagen III is fine and used for supporting the skin softness and tenderness and enabling the skin to be fine and elastic. The higher the content is, the more delicate and tender the skin can be, and the III type collagen can better recover the wound after the wound is produced and is not easy to leave scars.
Skin is the first barrier of the human body to the external environment, and skin damage can cause significant morbidity and mortality by mishandling. According to the world health organization, approximately 265000 people die each year in burn and scald patients alone, and six million patients need treatment. Skin necrosis or defects can be caused by various reasons such as skin cutting injury, skin avulsion injury, crush laceration injury, high-speed penetrating injury and the like, and the skin defects are called whether the skin defects are accompanied by exposure of nerves, blood vessels, tendons and bones. At present, the treatment of skin wounds which are difficult to heal is still a problem which needs to be solved clinically urgently, so that a plurality of dressings for promoting the healing of the skin wounds are produced at the same time, but the current clinical medical dressings cannot well meet the requirements. The existing medical dressing often has wound healing process disorder of different degrees in the reuse process, particularly has obstructed neovascularization, and brings psychological and economic burden to patients. Therefore, it is necessary to develop a safe and non-irritating dressing for healing skin wounds, which has good moisture retention and can promote the proliferation of skin wound cells and angiogenesis, so as to meet the requirements of repairing skin wounds which are difficult to heal, and the technical problem to be solved at present is urgent.
Disclosure of Invention
In view of this, the present invention provides a medical dressing with wound healing or repairing effect and a preparation method thereof, in order to overcome the defects of the prior art. The applicant discovers through a large number of experiments that the recombinant fibronectin-humanized collagen not only has the characteristics that fibronectin widely participates in the processes of cell migration, adhesion, proliferation, hemostasis, tissue repair and the like, mobilizes a mononuclear phagocyte system to remove harmful substances at the damaged tissue, has the growth factor-like effect, but also has the characteristics that the skin softness and tenderness are supported by type III collagen, the skin is fine and elastic, the wound can be better recovered, and scars are not easy to leave. The recombinant fibronectin-humanized collagen shows obvious synergistic effect of fibronectin and collagen, so that the skin can be comprehensively repaired, and the skin is more young, compact and plump.
The invention provides a medical dressing composition of recombinant fibronectin-humanized collagen for skin repair, which is characterized by comprising the following components in percentage by weight:
the raw materials of the composition comprise, by mass, 0.01-0.1% of active peptide, 0.05-0.5% of recombinant fibronectin-humanized collagen, 0.5-5% of alginate, 0.5-5% of glycerol and the balance of water.
Furthermore, the active peptide is a combination of tripeptide-1, pentapeptide-3, hexapeptide-9, hexapeptide-10 and acetyl tetrapeptide-9, and the weight ratio of any two polypeptides is 1:1-5: 1.
Further, the recombinant fibronectin-humanized collagen is lyophilized powder or 0.05-0.1% aqueous solution.
Further, the alginate is formed by orderly constructing fibers of the alginate, is of a single-layer sheet structure and has a microporous structure which is uniformly distributed, and the pore area of the microporous structure is 300-30000 mu m 2 . Preferably, the alginate is one or more of sodium alginate, potassium alginate and ammonium alginate, and the molecular weight of the alginate is 2000-200000. Preferably, the gram weight of the alginate dressing is 60-120 g/cm 2 . Preferably, the alginate dressing has a porosity of 20-80%, and the pores are triangular or other shapes.
Further, the purity of the glycerin is 99% or more.
Further, the water is deionized water.
Further, the base material is a fiber fabric or a nonwoven fabric. Further, the fiber fabric is at least one of cotton, wool, silk, hemp, bamboo, wood pulp, viscose, chitosan fiber, activated carbon fiber, terylene, chinlon, polypropylene fiber, spandex, aramid fiber, acetate fiber and polyurethane fiber.
Further, the preparation method of the dressing composition comprises the following steps: preparing active peptide and water, preparing active peptide aqueous solution, adding recombinant fibronectin-humanized collagen solution or dissolving dry product in the mixed solution, adding alginate and glycerol, stirring at high speed, and mixing to obtain gel dressing.
Further, the rotation speed of the stirring is 400-800 rpm.
Further, the stirring temperature is less than or equal to 35 ℃.
Various products developed by the composition can be used for repairing the skin of the face, neck, hands, feet and body of a human body, and also can be used for repairing the skin around eyes and improving the edema and dark circles of the eyes.
The composition of the invention is widely developed into medical dressings, and can be used for treating clinical wounds, skin diseases and the like.
Detailed Description
The present invention will be described in further detail with reference to examples, but the embodiments of the invention are not limited thereto.
Example 1
The functional medical dressing of this embodiment includes a dressing composition and a dressing core;
the dressing composition comprises the following components in parts by weight:
the dressing core is cotton gauze.
As described aboveIn the functional medical auxiliary material, the purified water has the resistivity of more than 0.1 x 10 6 Omega cm of water; the water is prepared by a reverse osmosis method.
In the functional medical dressing, the rotation speed of the stirring is 600 rpm.
In the functional medical dressing, the heating temperature is within 35 ℃.
In the functional medical dressing, the preparation method comprises the following steps:
dissolving 0.02 part of active peptide in 50 parts of water, preparing an aqueous solution of the active peptide, adding 0.4 part of recombinant fibronectin-humanized collagen solution or dissolving a dry product in the mixed solution, adding 1 part of sodium alginate and 2 parts of glycerol into 30 parts of purified water, stirring at a high speed, adding the aqueous solution of the active peptide and the recombinant fibronectin-humanized collagen into the aqueous solution of the sodium alginate and the glycerol, stirring at a high speed, and fully mixing to prepare the gel-packed dressing.
Example 2
The functional medical dressing of this embodiment comprises a dressing composition and a dressing core;
the dressing composition comprises the following components in parts by weight:
the dressing core is cotton gauze.
In the functional medical auxiliary material, the purified water has resistivity more than 0.1 x 10 6 Omega cm of water; the water is prepared by a reverse osmosis method.
In the functional medical dressing, the rotation speed of the stirring is 600 rpm.
In the functional medical dressing, the heating temperature is within 35 ℃.
In the functional medical dressing, the preparation method comprises the following steps:
dissolving 0.02 part of active peptide in 50 parts of water, preparing an active peptide aqueous solution, adding 0.5 part of recombinant fibronectin-humanized collagen solution or dissolving a dry product in the mixed solution, adding 1 part of sodium alginate and 2 parts of glycerol into 30 parts of purified water, stirring at a high speed, adding the active peptide and recombinant fibronectin-humanized collagen aqueous solution into the aqueous solution of sodium alginate and glycerol, stirring at a high speed, and fully mixing to prepare the gel dressing.
Comparative example 1
The functional medical dressing of this embodiment includes a dressing composition and a dressing core;
the dressing composition comprises the following components in parts by weight:
the dressing core is cotton gauze.
In the functional medical auxiliary material, the purified water has resistivity more than 0.1 x 10 6 Ω cm of water; the water is prepared by a reverse osmosis method.
In the functional medical dressing, the rotation speed of the stirring is 600 rpm.
In the functional medical dressing, the heating temperature is within 35 ℃.
In the functional medical dressing, the preparation method comprises the following steps:
preparing 50 parts of water, adding 0.5 part of recombinant fibronectin-humanized collagen solution or dissolving a dry product into the mixed solution, adding 1 part of sodium alginate and 2 parts of glycerol into 30 parts of purified water, stirring at a high speed, adding the recombinant fibronectin-humanized collagen solution into the aqueous solution of the sodium alginate and the glycerol, stirring at a high speed, and fully mixing to prepare the gel dressing.
Comparative example 2
The functional medical dressing of this embodiment comprises a dressing composition and a dressing core;
the dressing composition comprises the following components in parts by weight:
the dressing core is cotton gauze.
In the functional medical auxiliary material, the purified water has resistivity more than 0.1 x 10 6 Omega cm of water; the water is prepared by a reverse osmosis method.
In the functional medical dressing, the rotation speed of the stirring is 600 rpm.
In the functional medical dressing, the heating temperature is within 35 ℃.
In the functional medical dressing, the preparation method comprises the following steps:
dissolving 0.02 part of active peptide in 50 parts of water, adding 1 part of sodium alginate and 2 parts of glycerol into 30 parts of purified water, stirring at high speed, finally adding the active peptide aqueous solution into the aqueous solution of sodium alginate and glycerol, stirring at high speed, and fully mixing to prepare the gel dressing.
Test example
Cell repair assay
10 male Goto-Kakizaki rats with the body weight of between 180 and 200g are selected and provided by the experimental animal center in Shanghai city, and the related operations are strict aseptic operations to exclude the influence of bacterial infection factors. Using an SH04-YLS-5Q desk-top dismantling machine temperature-control scald apparatus on one side of the back of a mouse, scalding the mouse for 12 minutes at 90 ℃/0.5kg to generate a second-degree burn with a diameter of 18mm, randomly dividing the burn into 5 groups of 2, wherein the first group is a control group, treating the wound with 0.2mL of physiological saline every day, and the rest groups are respectively treated with the dressing composition for promoting the rapid healing of the wound prepared in the examples 1-2 and the comparative examples 1-2 with 0.2mL of physiological saline every day, taking pictures on the 0 th, 5 th and 10 th days, calculating the area of the wound by using IPP software, and calculating the healing rate of the wound.
The test results are shown in table 1.
TABLE 1 wound healing Rate
| Wound healing Rate of 5 days | 10 days wound healing rate | |
| Example 1 | 7.8％ | 58.8％ |
| Example 2 | 10.5％ | 75.3％ |
| Comparative example 1 | 9.7％ | 72.8％ |
| Comparative example 2 | 3.6％ | 37.2％ |
| Control group | 3.2％ | 34.8％ |
The above table shows that the dressing composition for promoting rapid wound repair provided by the invention has good capability of promoting wound repair, although the 5-day healing rate is not much different from that of a control group, the 10-day healing rate is obviously improved compared with that of the control group, and the highest healing rate can reach 75.3%. Meanwhile, the comparison of the examples and the comparative examples shows that the recombinant fibronectin-humanized collagen is a key component in the dressing composition and can effectively accelerate wound repair.
Claims (9)
1. A medical dressing composition with a skin repairing function is characterized in that: the raw materials of the composition comprise, by mass, 0.01-0.1% of active peptide, 0.05-0.5% of recombinant fibronectin-humanized collagen, 0.5-5% of alginate, 0.5-5% of glycerol and the balance of water.
2. The medical dressing composition with the function of repairing skin as claimed in claim 1, wherein the active peptide is a combination of tripeptide-1, pentapeptide-3, hexapeptide-9, hexapeptide-10 and acetyl tetrapeptide-9, and the weight ratio of any two polypeptides is 1:1-5: 1.
3. The medical dressing composition with the function of repairing skin according to claim 1, wherein the recombinant fibronectin-humanized collagen is lyophilized powder or 0.05-0.1% aqueous solution.
4. The medical dressing composition with the function of repairing skin according to claim 1, wherein the alginate is formed by orderly constructing alginate fibers, is of a single-layer sheet-shaped structure and has a uniformly distributed microporous structure, and the pore area of the microporous structure is 300-30000 μm 2 . Preferably, the alginate is one or more of sodium alginate, potassium alginate and ammonium alginate, and the molecular weight of the alginate is 2000-200000. The medical dressing composition having a skin-repairing function according to claim 1, wherein the glycerin has a purity of 99% or more.
5. The medical dressing composition with the function of repairing skin as claimed in claim 1, wherein the water is deionized water.
6. The medical dressing composition with skin repairing function according to claim 1, wherein the base material is a fiber fabric or a non-woven fabric. Further, the fiber fabric is at least one of cotton, wool, silk, hemp, bamboo, wood pulp, viscose, chitosan fiber, activated carbon fiber, terylene, chinlon, polypropylene fiber, spandex, aramid fiber, acetate fiber and polyurethane fiber.
7. The medical dressing composition with skin-repairing function according to claim 1, wherein:
the preparation method of the dressing composition comprises the following steps: preparing active peptide and water, preparing active peptide aqueous solution, adding recombinant fibronectin-humanized collagen solution or dissolving dry product in the mixed solution, adding alginate and glycerol, stirring at high speed, and mixing to obtain gel dressing.
8. The method for preparing a medical dressing composition with skin healing function according to claim 8, wherein the rotation speed of the stirring is 400-800 rpm.
9. The method for preparing a medical dressing composition with skin repairing function according to claim 8, wherein the stirring temperature is 35 ℃ or lower.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210896194.2A CN115089755A (en) | 2022-07-28 | 2022-07-28 | Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210896194.2A CN115089755A (en) | 2022-07-28 | 2022-07-28 | Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115089755A true CN115089755A (en) | 2022-09-23 |
Family
ID=83299846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210896194.2A Pending CN115089755A (en) | 2022-07-28 | 2022-07-28 | Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115089755A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737902A (en) * | 2022-11-07 | 2023-03-07 | 重庆正仁医疗器械有限公司 | Medical recombinant III-type humanized collagen gel |
| CN116173289A (en) * | 2022-12-29 | 2023-05-30 | 海南众森生物科技有限公司 | Functional dressing containing recombinant human collagen and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106362193A (en) * | 2016-11-07 | 2017-02-01 | 广州润虹医药科技有限公司 | Novel alginate dressing and preparation method thereof |
| CN111407685A (en) * | 2020-04-29 | 2020-07-14 | 苏州美尚洁生物科技有限公司 | Anti-aging composition of recombinant fibronectin-human-like collagen and preparation method thereof |
| CN111658818A (en) * | 2020-06-23 | 2020-09-15 | 湖南美媛本草生物工程有限公司 | Medical repair dressing and application thereof |
| CN114470314A (en) * | 2022-02-15 | 2022-05-13 | 海雅美生物技术(珠海)有限公司 | Recombinant humanized collagen gel dressing and preparation method and application thereof |
-
2022
- 2022-07-28 CN CN202210896194.2A patent/CN115089755A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106362193A (en) * | 2016-11-07 | 2017-02-01 | 广州润虹医药科技有限公司 | Novel alginate dressing and preparation method thereof |
| CN111407685A (en) * | 2020-04-29 | 2020-07-14 | 苏州美尚洁生物科技有限公司 | Anti-aging composition of recombinant fibronectin-human-like collagen and preparation method thereof |
| CN111658818A (en) * | 2020-06-23 | 2020-09-15 | 湖南美媛本草生物工程有限公司 | Medical repair dressing and application thereof |
| CN114470314A (en) * | 2022-02-15 | 2022-05-13 | 海雅美生物技术(珠海)有限公司 | Recombinant humanized collagen gel dressing and preparation method and application thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737902A (en) * | 2022-11-07 | 2023-03-07 | 重庆正仁医疗器械有限公司 | Medical recombinant III-type humanized collagen gel |
| CN116173289A (en) * | 2022-12-29 | 2023-05-30 | 海南众森生物科技有限公司 | Functional dressing containing recombinant human collagen and preparation method and application thereof |
| CN116173289B (en) * | 2022-12-29 | 2023-11-17 | 海南众森生物科技有限公司 | Functional dressing containing recombinant human collagen and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115089755A (en) | Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof | |
| Moraes et al. | Bacterial cellulose/collagen hydrogel for wound healing | |
| CN107551324B (en) | Preparation and application of suturable hard membrane repairing material | |
| CN105031740B (en) | A kind of biomimetic prosthetic skin with waterproof and breathable function and preparation method thereof | |
| WO2016004212A1 (en) | Hydrogels for treating and ameliorating wounds and methods for making and using them | |
| CN103463668A (en) | Preparation method of porous dressing of silk fibroin-calcium alginate biological wound | |
| Streit et al. | Apligraf–a living human skin equivalent for the treatment of chronic wounds | |
| CN113058070B (en) | Rapid hemostatic dressing and preparation method thereof | |
| CN106309150B (en) | Medical collagen dressing and preparation method and application thereof | |
| CN102357242B (en) | Recombination cattle alkaline fibroblast growth factor gel | |
| CN105797203A (en) | Alginate fiber based collagen sponge dressing and preparation method thereof | |
| CN108543064A (en) | A kind of quick reparation liquid and preparation method thereof for burn and scald | |
| CN114099476A (en) | Functional gel layer, scar patch and preparation method thereof | |
| CN106350560B (en) | Preparation method of fish protein peptide, fish protein peptide obtained by preparation method and application of fish protein peptide | |
| CN109985271B (en) | Composite collagen dressing for healing-difficult wound repair and preparation method thereof | |
| CN111097066A (en) | Medical dressing capable of inhibiting scar generation and promoting wound healing and preparation method thereof | |
| CN107441479B (en) | Marine active peptide/chitin burn ointment for treating scald and preparation method thereof | |
| CN109700998A (en) | A kind of compound skin injury regeneration renovation agent and preparation method thereof | |
| Tseomashko et al. | New hybrid materials for wound cover dressings | |
| CN113877001A (en) | Silk fibroin composite gel for injection | |
| CN103386145A (en) | Wound healing dressing containing carrageenan, and preparation method and application of wound healing dressing | |
| CN105749333A (en) | Medical dressing of hyaluronic acid and preparation method of medical dressing | |
| RU2543344C2 (en) | Method of treating trophic ulcers | |
| CN113274410A (en) | Application of exosome hydrogel complex in preparation of medicine for repairing skin scar | |
| Matthews-Brzozowska et al. | Revitalization of facial skin based on preparations of patient own blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220923 |
|
| RJ01 | Rejection of invention patent application after publication |